Skip to main content
SpringerLink
Log in

Lung Transplantation in Interstitial Lung Disease

  • Chapter
  • First Online:
Pulmonary Hypertension and Interstitial Lung Disease

Abstract

Advanced interstitial lung disease (ILD) that failed medical therapy is a common indication for lung transplantation. The first successful lung transplantation was performed in a patient with idiopathic pulmonary fibrosis. With the implementation of the lung allocation score in 2005, idiopathic pulmonary fibrosis has surpassed chronic obstructive pulmonary disease as the most common indication of lung transplantation. In the context of lung transplantation, interstitial lung diseases can be broadly grouped into idiopathic interstitial pneumonias, interstitial lung disease due to connective tissue disease (CTD), and pulmonary sarcoidosis with or without pulmonary hypertension. Idiopathic pulmonary fibrosis is the most common of the idiopathic interstitial pneumonia, followed by nonspecific interstitial pneumonia. The most common interstitial lung disease due to connective tissue disease that leads to lung transplantation is scleroderma-associated ILD. Others forms of ILD-CTD include rheumatoid arthritis, mixed connective tissue disease, and dermatomyositis/polymyositis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the pulmonary transplantation council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2015;34(1):1–15.

    Article  PubMed  Google Scholar 

  2. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest J. 2003;124(3):922–8.

    Article  Google Scholar 

  3. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362–70.

    Article  PubMed  Google Scholar 

  4. Shorr AF, Helman DL, Davies DB, Nathan SD. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest J. 2004;125(3):990–6.

    Article  Google Scholar 

  5. Arcasoy SM, Christie JD, Pochettino A, Rosengard BR, Blumenthal NP, Bavaria JE, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest J. 2001;120(3):873–80.

    Article  CAS  Google Scholar 

  6. Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J. 2012;39(6):1520–33. doi:10.1183/09031936.00175511.

    Article  PubMed  Google Scholar 

  7. Lynch JP, Belperio JA, Saggar R, Fishbein MC, Saggar R. Pulmonary hypertension complicating connective tissue disease. Semin Respir Crit Care Med. 2013;34(5):581–99.

    Article  PubMed  Google Scholar 

  8. Shitrit D, Amital A, Peled N, Raviv Y, Medalion B, Saute M, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant. 2009;23(2):178–83.

    Article  PubMed  Google Scholar 

  9. Schachna L, Medsger TA, Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006;54(12):3954–61.

    Article  PubMed  Google Scholar 

  10. Saggar R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J. 2010;36(4):893–900. doi:10.1183/09031936.00139809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sottile PD, Iturbe D, Katsumoto TR, Connolly MK, Collard HR, Leard LA, et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation. 2013;95(7):975–80. doi:10.1097/TP.0b013e3182845f23.

    Article  PubMed  PubMed Central  Google Scholar 

  12. De Cruz S, Ross D. Lung transplantation in patients with scleroderma. Curr Opin Rheumatol. 2013;25(6):714–8. doi:10.1097/01.bor.0000434670.39773.a8.

    Article  PubMed  Google Scholar 

  13. Judge EP, Fabre A, Adamali HI, Egan JJ. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012;40(1):93–100. doi:10.1183/09031936.00115511.

    Article  PubMed  Google Scholar 

  14. Andersen CU, Mellemkjær S, Hilberg O, Nielsen-Kudsk JE, Simonsen U, Bendstrup E. Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test. Respir Med. 2012;106(6):875–82.

    Article  PubMed  Google Scholar 

  15. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31(6):1357–67. doi:10.1183/09031936.00171307.

    Article  CAS  PubMed  Google Scholar 

  16. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest J. 2006;129(3):746–52.

    Article  Google Scholar 

  17. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715–21. doi: 09031936.00107206 [pii]

    Article  CAS  PubMed  Google Scholar 

  18. Corte TJ, Wort SJ, Gatzoulis MA, Engel R, Giannakoulas G, Macdonald PM, et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J. 2010;36(4):819–25. doi:10.1183/09031936.00173509.

    Article  CAS  PubMed  Google Scholar 

  19. Corte TJ, Wort SJ, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax. 2009;64(10):883–8. doi:10.1136/thx.2008.112847.

    Article  CAS  PubMed  Google Scholar 

  20. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest J. 2010;138(6):1383–94.

    Article  Google Scholar 

  21. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of Bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(1):75–81.

    Article  CAS  PubMed  Google Scholar 

  22. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641–9.

    Article  PubMed  Google Scholar 

  23. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;2010(363):620–8.

    Google Scholar 

  24. Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med. 2009;30(4):429–39.

    Article  PubMed  Google Scholar 

  25. Singer LG, Chowdhury NA, Faughnan ME, Granton J, Keshavjee S, Marras TK, et al. Effects of recipient age and diagnosis on health-related quality-of-life benefit of lung transplantation. Am J Respir Crit Care Med. 2015;192(8):965–73.

    Article  PubMed  Google Scholar 

  26. Genao L, Whitson H, Zaas D, Sanders L, Schmader K. Functional status after lung transplantation in older adults in the Post-Allocation score era. Am J Transplant. 2013;13(1):157–66.

    Article  CAS  PubMed  Google Scholar 

  27. Lederer DJ, Wilt JS, D'Ovidio F, Bacchetta MD, Shah L, Ravichandran S, et al. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med. 2009;180(9):887–95.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy SL, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187(5):527–34.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kanasky WF, Anton SD, Rodrigue JR, Perri MG, Szwed T, Baz MA. Impact of body weight on long-term survival after lung transplantation. Chest J. 2002;121(2):401–6.

    Article  Google Scholar 

  30. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.

    Article  PubMed  Google Scholar 

  31. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.

    Article  PubMed  Google Scholar 

  32. Liu H, Drew P, Cheng Y, Visner GA. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. J Thorac Cardiovasc Surg. 2005;130(3):852–8.

    Article  CAS  PubMed  Google Scholar 

  33. Riddell P, Minnis P, Ging P, Egan J. P242 pirfenidone as a bridge to lung transplantation in patients with progressive IPF. Thorax. 2014;69(Suppl 2):A183.

    Article  Google Scholar 

  34. Patterson C, Durheim M, Palmer S, Copeland CF, Snyder L. A national survey of practice and perceptions regarding anti-fibrotic medication in lung transplant recipients. J Heart Lung Transplant. 2016;35(4):S226–7.

    Article  Google Scholar 

  35. Gottlieb J, Warnecke G, Hadem J, Dierich M, Wiesner O, Fühner T, et al. Outcome of critically ill lung transplant candidates on invasive respiratory support. Intensive Care Med. 2012;38(6):968–75.

    Article  PubMed  Google Scholar 

  36. Fuehner T, Kuehn C, Hadem J, Wiesner O, Gottlieb J, Tudorache I, et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med. 2012;185:763–8.

    Article  PubMed  Google Scholar 

  37. Rehder KJ, Turner DA, Hartwig MG, Williford WL, Bonadonna D, Walczak RJ Jr, et al. Active rehabilitation during extracorporeal membrane oxygenation as a bridge to lung transplantation. Respir Care. 2013;58(8):1291–8. doi:10.4187/respcare.02155.

    Article  PubMed  Google Scholar 

  38. Olsson KM, Simon A, Strueber M, Hadem J, Wiesner O, Gottlieb J, et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant. 2010;10(9):2173–8.

    Article  CAS  PubMed  Google Scholar 

  39. Rosenzweig EB, Brodie D, Abrams DC, Agerstrand CL, Bacchetta M. Extracorporeal membrane oxygenation as a novel bridging strategy for acute right heart failure in group 1 pulmonary arterial hypertension. ASAIO J. 2014;60(1):129–33. doi:10.1097/MAT.0000000000000021.

    Article  CAS  PubMed  Google Scholar 

  40. Fischer S, Bohn D, Rycus P, Pierre AF, de Perrot M, Waddell TK, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the extracorporeal life support organization (ELSO) registry. J Heart Lung Transplant. 2007;26(5):472–7.

    Article  PubMed  Google Scholar 

  41. Trudzinski FC, Kaestner F, Schäfers H, Fähndrich S, Seiler F, Böhmer P, et al. Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. Am J Respir Crit Care Med. 2016;193(5):527–33.

    Article  CAS  PubMed  Google Scholar 

  42. Thabut G, Christie JD, Ravaud P, Castier Y, Dauriat G, Jebrak G, et al. Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med. 2009;151(11):767–74.

    Article  PubMed  Google Scholar 

  43. Nathan SD, Shlobin OA, Ahmad S, Burton NA, Barnett SD, Edwards E. Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. J Heart Lung Transplant. 2010;29(10):1165–71.

    Article  PubMed  Google Scholar 

  44. Meyer DM, Edwards LB, Torres F, Jessen ME, Novick RJ. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg. 2005;79(3):950–7.

    Article  PubMed  Google Scholar 

  45. Massad MG, Powell CR, Kpodonu J, Tshibaka C, Hanhan Z, Snow NJ, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg. 2005;29(11):1510–5.

    Article  PubMed  Google Scholar 

  46. Fadel E, Mercier O, Mussot S, Leroy-Ladurie F, Cerrina J, Chapelier A, et al. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg. 2010;38(3):277–84. doi:10.1016/j.ejcts.2010.02.039.

    Article  PubMed  Google Scholar 

  47. Kramer MR, Valantine HA, Marshall SE, Starnes VA, Theodore J. Recovery of the right ventricle after single-lung transplantation in pulmonary hypertension. Am J Cardiol. 1994;73(7):494–500.

    Article  CAS  PubMed  Google Scholar 

  48. Toyooka S, Sano Y, Yamane M, Oto T, Okazaki M, Kusano KF, et al. Long-term follow-up of living-donor single lobe transplantation for idiopathic pulmonary arterial hypertension in a child. J Thorac Cardiovasc Surg. 2008;135(2):451–2.

    Article  PubMed  Google Scholar 

  49. Sherman W, Rabkin DG, Ross D, Saggar R, Lynch JP, Belperio J, et al. Lung transplantation and coronary artery disease. Ann Thorac Surg. 2011;92(1):303–8.

    Article  PubMed  Google Scholar 

  50. Castleberry A, Martin J, Osho A, Hartwig M, Hashmi Z, Zanotti G, et al. Coronary revascularization in lung transplant recipients with concomitant coronary artery disease. Am J Transplant. 2013;13(11):2978–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Lee R, Meyers BF, Sundt TM, Trulock EP, Patterson GA. Concomitant coronary artery revascularization to allow successful lung transplantation in selected patients with coronary artery disease. J Thorac Cardiovasc Surg. 2002;124(6):1250–1.

    Article  PubMed  Google Scholar 

  52. Lee R, Meyers BF, Sundt TM, Trulock EP, Patterson GA. Atrial fibrillation following lung transplantation: double but not single lung transplant is associated with long-term freedom from paroxysmal atrial fibrillation. Eur Heart J. 2010;31(22):2774–82. doi:10.1093/eurheartj/ehq224.

    Article  PubMed  Google Scholar 

  53. Thompson ML, Flynn JD, Clifford TM. Pharmacotherapy of lung transplantation: an overview. J Pharm Pract. 2013;26(1):5–13. doi:10.1177/0897190012466048.

    Article  PubMed  Google Scholar 

  54. Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc. 2009;6(1):39–46.

    Article  PubMed  Google Scholar 

  55. Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007;175(5):507–13.

    Article  PubMed  Google Scholar 

  56. Whitson BA, Nath DS, Johnson AC, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg. 2006;131(1):73–80.

    Article  PubMed  Google Scholar 

  57. Fang A, Studer S, Kawut SM, Ahya VN, Lee J, Wille K, et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest J. 2011;139(4):782–7.

    Article  Google Scholar 

  58. Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S, Brown J, Catherwood E, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010;25(9):3090–6. doi:10.1093/ndt/gfq141.

    Article  PubMed  Google Scholar 

  59. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The registry of the international society for heart and lung transplantation: thirty-second official adult lung and heart-lung transplantation report—2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34(10):1264–77.

    Article  PubMed  Google Scholar 

  60. Ruiz I, Gavalda J, Monforte V, Len O, Román A, Bravo C, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;6(1):178–82.

    Article  CAS  PubMed  Google Scholar 

  61. Husain S, Paterson D, Studer S, Pilewski J, Crespo M, Zaldonis D, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6(12):3008–16.

    Article  CAS  PubMed  Google Scholar 

  62. Neoh C, Snell G, Kotsimbos T, Levvey B, Morrissey CO, Slavin M, et al. Antifungal prophylaxis in lung transplantation—a world-wide survey. Am J Transplant. 2011;11(2):361–6.

    Article  CAS  PubMed  Google Scholar 

  63. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11. doi:10.1086/651262.

    Article  PubMed  Google Scholar 

  64. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish network of infection in transplantation) cohort. Clin Infect Dis. 2009;48(12):1657–65. doi:10.1086/599035.

    Article  PubMed  Google Scholar 

  65. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779–95. doi:10.1097/TP.0b013e3181cee42f.

    Article  PubMed  Google Scholar 

  66. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181(12):1391–6.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, et al. The registry of the international society for heart and lung transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012;31(10):1073–86. doi:10.1016/j.healun.2012.08.004.

    Article  PubMed  Google Scholar 

  68. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, et al. Extended valganciclovir prophylaxis in D+/R− kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427–31.

    Article  CAS  PubMed  Google Scholar 

  69. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(s4):93–106.

    Article  CAS  PubMed  Google Scholar 

  70. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation. 2006;81(12):1645–52. doi:10.1097/01.tp.0000226071.12562.1a.

    Article  PubMed  Google Scholar 

  71. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008;46(6):840–6. doi:10.1086/528718.

    Article  PubMed  Google Scholar 

  72. Sato M, Waddell TK, Wagnetz U, Roberts HC, Hwang DM, Haroon A, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant. 2011;30(7):735–42.

    Article  PubMed  Google Scholar 

  73. Ofek E, Sato M, Saito T, Wagnetz U, Roberts HC, Chaparro C, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol. 2013;26(3):350–6.

    Article  CAS  PubMed  Google Scholar 

  74. Vos R, Verleden SE, Verleden GM. Chronic lung allograft dysfunction: evolving practice. Curr Opin Organ Transplant. 2015;20(5):483–91.

    Article  CAS  PubMed  Google Scholar 

  75. Belperio JA, Weigt SS, Fishbein MC, Lynch JP III. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc. 2009;6(1):108–21.

    Article  CAS  PubMed  Google Scholar 

  76. Meyers BF, Lynch JP, Trulock EP, Guthrie T, Cooper JD, Patterson GA. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg. 2000;120(1):99–107.

    Article  CAS  PubMed  Google Scholar 

  77. Bartels MN, Armstrong HF, Gerardo RE, Layton AM, Emmert-Aronson BO, Sonett JR, et al. Evaluation of pulmonary function and exercise performance by cardiopulmonary exercise testing before and after lung transplantation. Chest. 2011;140(6):1604–11.

    Article  PubMed  Google Scholar 

  78. Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015;313(9):936–48.

    Article  CAS  PubMed  Google Scholar 

  79. Khan IY, Singer LG, de Perrot M, Granton JT, Keshavjee S, Chau C, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med. 2013;107(12):2081–7.

    Article  PubMed  Google Scholar 

  80. Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis–associated interstitial lung disease after lung transplantation. J Heart Lung Transplant. 2014;33(5):514–20.

    Article  PubMed  Google Scholar 

  81. Takagishi T, Ostrowski R, Alex C, Rychlik K, Pelletiere K, Tehrani R. Survival and extrapulmonary course of connective tissue disease after lung transplantation. J Clin Rheumatol. 2012;18(6):283–9.

    Article  PubMed  Google Scholar 

  82. Studer SM, Levy RD, McNeil K, Orens JB. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J. 2004;24(4):674–85.

    Article  CAS  PubMed  Google Scholar 

  83. Gries CJ, Mulligan MS, Edelman JD, Raghu G, Curtis JR, Goss CH. Lung allocation score for lung transplantation: impact on disease severity and survival. Chest J. 2007;132(6):1954–61.

    Article  Google Scholar 

  84. Valapour M, Skeans MA, Smith JM, Edwards LB, Cherikh WS, Callahan ER, et al. Lung. Am J Transplant. 2016;16:141–68.

    Article  PubMed  Google Scholar 

  85. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–91.

    Article  PubMed  Google Scholar 

  86. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962–9.

    Article  PubMed  Google Scholar 

  87. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher. 2006;21(1):72–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Pulmonary and Critical Care, David Geffen School of Medicine at University of California, Los Angeles, CA, USA

    Cynthia Kim MD

  2. Department of Thoracic Medicine and Surgery, Temple University School of Medicine, 3401 North Broad St, Philadelphia, PA, 19140, USA

    Francis Cordova MD & Yoshiya Toyoda MD, PhD

Authors
  1. Cynthia Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francis Cordova MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshiya Toyoda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francis Cordova MD .

Editor information

Editors and Affiliations

  1. Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

    Robert P. Baughman

  2. Regional Hospital Aosta and University of Genoa, Genoa, Italy

    Roberto G. Carbone

  3. Inova Fairfax Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, Virginia, USA

    Steven D. Nathan

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Kim, C., Cordova, F., Toyoda, Y. (2017). Lung Transplantation in Interstitial Lung Disease. In: Baughman, R., Carbone, R., Nathan, S. (eds) Pulmonary Hypertension and Interstitial Lung Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-49918-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-49918-5_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-49916-1

  • Online ISBN: 978-3-319-49918-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation